Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

LEGN

Legend Biotech (LEGN)

Legend Biotech Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LEGN
DateTimeSourceHeadlineSymbolCompany
06/03/20244:05PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
06/03/20244:00PMBusiness WireLegend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHANASDAQ:LEGNLegend Biotech Corporation
05/29/20248:00AMBusiness WireLegend Biotech to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:LEGNLegend Biotech Corporation
05/23/20245:00PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
05/23/20245:00PMBusiness WireLegend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHANASDAQ:LEGNLegend Biotech Corporation
05/13/20247:10AMIH Market NewsU.S. Futures Climb Amid High Expectations for Inflation Data; Global Markets Show Mixed ReactionsNASDAQ:LEGNLegend Biotech Corporation
05/13/20247:01AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
05/13/20247:00AMBusiness WireLegend Biotech Reports First Quarter 2024 Results and Recent HighlightsNASDAQ:LEGNLegend Biotech Corporation
04/22/20241:05PMBusiness WireCARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
04/11/20248:00AMBusiness WireLegend Biotech to Host Investor Conference Call on First Quarter 2024 ResultsNASDAQ:LEGNLegend Biotech Corporation
04/05/202411:30PMBusiness WireLegend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
03/19/20248:30AMBusiness WireLegend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) ReportNASDAQ:LEGNLegend Biotech Corporation
03/15/20243:15PMBusiness WireCARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
03/11/20247:52AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
03/11/20247:00AMBusiness WireLegend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent HighlightsNASDAQ:LEGNLegend Biotech Corporation
03/11/20246:39AMIH Market NewsU.S. Index Futures Dip Ahead of Inflation Data and Oracle’s Earnings; Oil Prices Edge HigherNASDAQ:LEGNLegend Biotech Corporation
02/28/20246:46PMEdgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:LEGNLegend Biotech Corporation
02/27/20247:47PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LEGNLegend Biotech Corporation
02/23/20241:10PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LEGNLegend Biotech Corporation
02/23/20247:16AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
02/23/20247:15AMBusiness WireLegend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of TherapyNASDAQ:LEGNLegend Biotech Corporation
02/14/20248:34PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LEGNLegend Biotech Corporation
02/13/20248:00AMBusiness WireLegend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 ResultsNASDAQ:LEGNLegend Biotech Corporation
01/23/20249:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
01/23/20247:30AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
01/09/20244:01PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
01/03/202411:28AMBusiness WireLegend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3NASDAQ:LEGNLegend Biotech Corporation
01/03/20248:30AMBusiness WireLegend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3NASDAQ:LEGNLegend Biotech Corporation
01/02/20248:30AMBusiness WireLegend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:LEGNLegend Biotech Corporation
12/27/202310:00AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LEGNLegend Biotech Corporation
 Showing the most relevant articles for your search:NASDAQ:LEGN